RecruitingNCT03263130

Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

Sponsor

Gelb, Arthur F., M.D.

Enrollment

60 participants

Start Date

Jan 1, 2017

Study Type

OBSERVATIONAL

Conditions

Emphysema COPD, Emphysema, Asthma COPD Overlap

Summary

The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).

Eligibility

Min Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating where exactly in the airways the blockage occurs when people with chronic lung conditions like COPD, emphysema, or asthma-COPD overlap breathe out, which could help doctors better understand and treat these conditions. **You may be eligible if...** - You have been diagnosed with asthma-COPD overlap (features of both asthma and COPD) - OR you are a smoker with a history of at least 15 pack-years and have emphysema, chronic bronchitis, or bronchiectasis **You may NOT be eligible if...** - You have never smoked - You have pulmonary fibrosis or any other lung or systemic disease besides the ones listed above Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.